High-tech spectacle blends with science engagement – SHINE – BEYOND A SINGLE STORY
A huge humanoid robot waves hands in the virtual world while humanoid robots walk the red carpet in real world.
Humanoid robots strutted down a red carpet alongside scientists and tech leaders at the opening of the 2025 Shanghai Science Festival on Saturday, blending a high-tech spectacle with public science engagement.
Held at Zhangjiang Science Hall, the event spotlighted China's rapidly advancing robotics industry, positioning Shanghai as a showcase for emerging technologies including AI, XR, and humanoid automation.
Fourier's founder and CEO Gu Jie, and vice president Zeng Xiang, walked the carpet with two humanoid robots developed by the company: GR-2 and N1.
Jiang Xiaowei / SHINE
Fourier's founder and CEO Gu Jie (second from the left) and vice president Zeng Xiang (left) with two humanoid robots developed by the company.
The GR-2 stands 1.75 meters tall, weighs 63 kilograms, and is designed for heavy lifting and interactive training. It can carry more than 10 kilograms and is being developed for physical labor tasks across industries.
The smaller N1 model focuses on endurance, and is capable of running for more than two hours on a single charge. It is also fully open-source, with all blueprints and code publicly available, offering developers around the world a platform for collaboration and experimentation.
'When a 1.75-meter-tall robot walks alongside a human on the red carpet, it's not just for show. It's a glimpse into what's possible,' said Gu. 'These robots have undergone tens of thousands of hours of testing across various terrains and scenarios.'
Another crowd-pleasing moment came from Agibot's A2 robot, which performed a tai chi routine while explaining the martial art in real time. The 1.69-meter-tall robot moved with surprising fluidity, drawing applause from the audience.
Ti Gong
Agibot's humanoid robot plays tai chi on the red carpet.
'The pace of development is incredible,' said Wang Chuang, Agibot's general product line president. 'Last year, some robots still stumbled while walking. This year, they're performing. The red carpet is a perfect stage to show how fast we're advancing.'
The company has hundreds of humanoid robots deployed in real-world settings, with each unit produced on a standardized manufacturing line – 'ready to use, like a car,' he added.
This year's red carpet also featured an upgraded AI-powered experience using XR. As guests walked, their movements were merged live with dynamic virtual environments – from an immersive 'brain universe' to surreal, aurora-lit dreamscapes – each reflecting the creativity and innovation behind their work.
Ti Gong
A purple ocean where a huge whale is swimming appears at the site when Jo Quinton-Tulloch, director of the UK's National Science and Media Museum, and Ni Minjing, director of the Shanghai Science and Technology Museum, walk on the red carpet.
Ti Gong
Ni Minjing, director of the Shanghai Science and Technology Museum and Quinton-Tulloch, director of the UK's National Science and Media Museum.
The event drew a diverse crowd: top scientists, start-up founders, science influencers, and young inventors.
International guests included Jo Quinton-Tulloch, director of the UK's National Science and Media Museum, and Cho Sook-kyoung, president of the Network for the Public Communication of Science and Technology (PCST).
One emotional highlight saw neuroscientist Mu-Ming Poo and cell biologist Yuan Junying encounter AI-generated younger versions of themselves.
Yuan embraced her 18-year-old self and said: 'I want to tell my 18-year-old self that you've made the right choice. That's something I truly believe.'
Ti Gong
Xu Jian, deputy director of the university's School of Media and Communication, unveils the 'Global Urban Science Communication Capacity Index 2025.'
The report assessed 40 major cities across six continents, ranking New York first, followed by London and Boston. Other Chinese cities included Beijing (7th), Hong Kong (12th), Taipei (22nd), Shenzhen (23rd), Hangzhou (25th), and Guangzhou (26th).
The index mainly looks at how well research institutions, companies, governments, and media share and communicate science with the public.
New York leads by excelling across scientific outreach, organized communication, and public engagement. London and Boston follow closely, thanks to their vibrant scientific communities and diverse communication channels.
Shanghai's high ranking reflects rapid growth in science communication. It leads in offline public participation (1st), ranks fourth in media-driven outreach, and fifth in scientists' communication impact.
Zeng emphasized the PCST 2027's vision.
'We want this conference to bring science closer to everyday life,' he said.
'By building an innovative science communication network across the Yangtze River Delta, Shanghai aims to become a global hub for science communication and innovation.
'This will strengthen China's influence worldwide and inspire more people, especially youth, to engage with science and become future scientists.'
READ SOURCE
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
22 minutes ago
- Miami Herald
MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks
With Mira-55 and Ketamir-2, MIRA is advancing complementary non-opioid therapies for two of the largest pain markets MIAMI, FLORIDA / ACCESS Newswire / July 3, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced positive preclinical data demonstrating that Mira-55, the Company's proprietary non-psychotropic marijuana analog, delivered morphine-comparable pain relief in a validated model of inflammatory pain-without causing local inflammation. Mira-55 is a next-generation analog of marijuana, engineered to selectively activate CB2 cannabinoid receptors, which are associated with anti-inflammatory and analgesic effects. Unlike THC, Mira-55 minimizes activation of CB1 receptors, reducing the risk of euphoria, sedation, and pro-inflammatory side effects. "These results reinforce the value of Mira-55 as a differentiated cannabinoid-based therapy with real clinical potential," said Erez Aminov, Chairman and CEO of MIRA. "We believe the drug's ability to match morphine's pain relief-without the baggage of addiction, sedation, or THC-like effects-makes Mira-55 an ideal candidate for large, underserved inflammatory pain markets. It's another step in building a non-opioid pain franchise that addresses both inflammatory and neuropathic pain." Study Overview and Key Findings Mira-55 was tested using the formalin model, a gold-standard preclinical method for studying inflammatory pain. In this model, formalin is injected into the rat's paw, producing a pain response that mimics human inflammatory pain. Pain sensitivity was assessed using Von Frey Filament testing, which measures tactile pain thresholds, and inflammation was measured by paw edema volume. Key findings: Mira-55 reduced pain sensitivity by approximately threefold, restoring thresholds to near-baseline analgesic effect was equivalent to morphine, the standard opioid comparator in the sedation or inflammatory swelling was observed with Mira-55 treatment. Importantly, following a scientific review, the U.S. Drug Enforcement Administration (DEA) determined that Mira-55 is not classified as a controlled substance. This designation supports the compound's long-term clinical and commercial viability and removes key barriers typically associated with cannabinoid-based drug development. These results build on prior data from a separate inflammatory pain model conducted by a leading U.S. academic research center, where Mira-55 blocked both thermal and mechanical hyperalgesia without increasing inflammation. In contrast, low-dose THC in that model exacerbated inflammation-further validating Mira-55's selective pharmacological profile. "Mira-55 offers the pain-relieving potential of cannabinoids without the liabilities traditionally seen in THC-based drugs," said Dr. Itzchak Angel, Chief Scientific Advisor at MIRA. "Its novel structure and unique profile with CB2 selectivity and non-scheduled DEA status make it a compelling candidate for treating inflammation-driven pain conditions that are poorly managed by today's standards." Strategic Fit Within MIRA's Pain Portfolio Mira-55 complements Ketamir-2, MIRA's clinical-stage NMDA receptor antagonist, which is advancing through Phase 1 development for neuropathic pain. While Ketamir-2 addresses nerve-related pain through central mechanisms, Mira-55 targets inflammatory pain through the endocannabinoid system. Together, they represent two mechanistically distinct, non-opioid approaches to treating chronic pain. "With Mira-55 and Ketamir-2, we now have two highly differentiated drug candidates with the potential to transform how inflammatory and neuropathic conditions are treated," added Aminov. "We're advancing each asset methodically, and we're energized by the momentum we've built across the pipeline." Corporate Update on SKNY Merger MIRA also announced continued progress on its previously disclosed acquisition of SKNY Pharmaceuticals, the developer of SKNY-1, a novel investigational therapy targeting both obesity and nicotine addiction. In recent studies, SKNY-1 demonstrated a 30% reduction in body weight without muscle loss, along with a reversal of nicotine cravings-highlighting its potential as a differentiated treatment in two major markets. The U.S. Securities and Exchange Commission (SEC) has completed its review of the merger proxy with no comments, allowing MIRA to proceed with shareholder approval and the final steps toward completing the transaction. "We are pleased to report that the SEC had no comments on our merger filing, which reflects the quality of our regulatory and business preparation," said Aminov. "This milestone allows us to advance toward shareholder approval with clarity and confidence as we prepare for the next phase of growth." Next Steps MIRA Pharmaceuticals is advancing Mira-55 toward an Investigational New Drug (IND) submission, with ongoing activities supporting future clinical development in inflammatory pain. The Company remains focused on progressing both lead programs-Mira-55 and Ketamir-2-toward their next regulatory and clinical milestones. About MIRA Pharmaceuticals, Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in areas such as neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. Cautionary Note Regarding Forward-Looking StatementsThis press release and the statements of MIRA's management related thereto contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA's current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA's potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA's programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at and on MIRA's website at MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact:Helga Moyainfo@ 432-9792 SOURCE: MIRA Pharmaceuticals
USA Today
23 minutes ago
- USA Today
MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks
With Mira-55 and Ketamir-2, MIRA is advancing complementary non-opioid therapies for two of the largest pain markets MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ('MIRA' or the 'Company'), a clinical-stage pharmaceutical company developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced positive preclinical data demonstrating that Mira-55, the Company's proprietary non-psychotropic marijuana analog, delivered morphine-comparable pain relief in a validated model of inflammatory pain-without causing local inflammation. Mira-55 is a next-generation analog of marijuana, engineered to selectively activate CB2 cannabinoid receptors, which are associated with anti-inflammatory and analgesic effects. Unlike THC, Mira-55 minimizes activation of CB1 receptors, reducing the risk of euphoria, sedation, and pro-inflammatory side effects. 'These results reinforce the value of Mira-55 as a differentiated cannabinoid-based therapy with real clinical potential,' said Erez Aminov, Chairman and CEO of MIRA. 'We believe the drug's ability to match morphine's pain relief-without the baggage of addiction, sedation, or THC-like effects-makes Mira-55 an ideal candidate for large, underserved inflammatory pain markets. It's another step in building a non-opioid pain franchise that addresses both inflammatory and neuropathic pain.' Study Overview and Key Findings Mira-55 was tested using the formalin model, a gold-standard preclinical method for studying inflammatory pain. In this model, formalin is injected into the rat's paw, producing a pain response that mimics human inflammatory pain. Pain sensitivity was assessed using Von Frey Filament testing, which measures tactile pain thresholds, and inflammation was measured by paw edema volume. Key findings: Mira-55 reduced pain sensitivity by approximately threefold, restoring thresholds to near-baseline levels. Its analgesic effect was equivalent to morphine, the standard opioid comparator in the study. No sedation or inflammatory swelling was observed with Mira-55 treatment. Importantly, following a scientific review, the U.S. Drug Enforcement Administration (DEA) determined that Mira-55 is not classified as a controlled substance. This designation supports the compound's long-term clinical and commercial viability and removes key barriers typically associated with cannabinoid-based drug development. These results build on prior data from a separate inflammatory pain model conducted by a leading U.S. academic research center, where Mira-55 blocked both thermal and mechanical hyperalgesia without increasing inflammation. In contrast, low-dose THC in that model exacerbated inflammation-further validating Mira-55's selective pharmacological profile. 'Mira-55 offers the pain-relieving potential of cannabinoids without the liabilities traditionally seen in THC-based drugs,' said Dr. Itzchak Angel, Chief Scientific Advisor at MIRA. 'Its novel structure and unique profile with CB2 selectivity and non-scheduled DEA status make it a compelling candidate for treating inflammation-driven pain conditions that are poorly managed by today's standards.' Strategic Fit Within MIRA's Pain Portfolio Mira-55 complements Ketamir-2, MIRA's clinical-stage NMDA receptor antagonist, which is advancing through Phase 1 development for neuropathic pain. While Ketamir-2 addresses nerve-related pain through central mechanisms, Mira-55 targets inflammatory pain through the endocannabinoid system. Together, they represent two mechanistically distinct, non-opioid approaches to treating chronic pain. 'With Mira-55 and Ketamir-2, we now have two highly differentiated drug candidates with the potential to transform how inflammatory and neuropathic conditions are treated,' added Aminov. 'We're advancing each asset methodically, and we're energized by the momentum we've built across the pipeline.' Corporate Update on SKNY Merger MIRA also announced continued progress on its previously disclosed acquisition of SKNY Pharmaceuticals, the developer of SKNY-1, a novel investigational therapy targeting both obesity and nicotine addiction. In recent studies, SKNY-1 demonstrated a 30% reduction in body weight without muscle loss, along with a reversal of nicotine cravings-highlighting its potential as a differentiated treatment in two major markets. The U.S. Securities and Exchange Commission (SEC) has completed its review of the merger proxy with no comments, allowing MIRA to proceed with shareholder approval and the final steps toward completing the transaction. 'We are pleased to report that the SEC had no comments on our merger filing, which reflects the quality of our regulatory and business preparation,' said Aminov. 'This milestone allows us to advance toward shareholder approval with clarity and confidence as we prepare for the next phase of growth.' Next Steps MIRA Pharmaceuticals is advancing Mira-55 toward an Investigational New Drug (IND) submission, with ongoing activities supporting future clinical development in inflammatory pain. The Company remains focused on progressing both lead programs-Mira-55 and Ketamir-2-toward their next regulatory and clinical milestones. About MIRA Pharmaceuticals, Inc. MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in areas such as neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. Cautionary Note Regarding Forward-Looking Statements This press release and the statements of MIRA's management related thereto contain 'forward-looking statements,' which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'seeks,' 'will,' and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA's current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA's potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA's programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at and on MIRA's website at MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact: Helga Moya info@ (786) 432-9792 SOURCE: MIRA Pharmaceuticals View the original press release on ACCESS Newswire
Business Insider
2 days ago
- Business Insider
How the US Air Force is keeping its decades-old stealth B-2 Spirit bomber lethal
The US Air Force's B-2 Spirit bomber is a highly effective strategic bomber built to penetrate tough battlespaces, but it's been flying for roughly three decades. Time takes a toll, meaning upgrades are needed to keep it lethal. The Air Force is working on making the B-2 harder to see and available more often as part of ongoing modernization efforts. Over the weekend, the Air Force Life Cycle Management Center Public Affairs released details on how they are tinkering with the bomber's software and hardware to keep at the top of its game. Key efforts are focused on improving maintenance speed, better stealth, and improved communications. "A lot of people talk about the B-2 as a legacy platform and that is incorrect: It is an operational platform conducting strikes today and if the flag goes up tomorrow, it will be one of the first platforms to conduct strikes," said Lt. Col Robert Allen, materiel leader for the B-2 Advanced Programs Branch. The B-2, made by Northrop Grumman, is an expensive $2 billion bomber that was controversial in its development, in part due to the high costs. It entered service with the Air Force in 1997 and first saw combat in the Kosovo War as part of Operation Allied Force. Most recently, seven B-2s dropped bombs on Iran's nuclear facilities in Fordow, Natanz, and Isfahan. The strategic bombers carried 14 GBU-57 Massive Ordnance Penetrator bunker-buster bombs, powerful, heavy munitions designed to penetrate hardened bunkers and deeply buried underground facilities. Each bomb weighs 15 tons. B-2 bombers are also capable of carrying nuclear payloads and are an important element of the US nuclear triad, which also includes intercontinental ballistic missiles and submarine-launched missiles. This flexibility in payload type and capacity makes the B-2 instrumental to the larger US military's strike options — and prompts continual investments in keeping it ahead of the curve. Quicker maintenance A bomber is only useful if it's ready to fly. The Air Force is working to ensure that the aircraft is ready when it needs to be by reducing downtime and increasing availability for what has traditionally been a maintenance-intensive aircraft. The service currently has 20 B-2s in active service, having lost one in a crash back in 2008. The B-2's significant maintenance overhaul, called program depot maintenance or PDM, that's done every nine years typically takes 470 days. It is "an exhaustive inspection, overhaul, and repair of the bomber, with much of the work focused on restoration of the bomber's Low Observable (LO) or stealth materials," the Air Force Life Cycle Management Center Public Affairs said in a statement last fall. But last October, the work was done in 379 days. The improvements to the maintenance process included doing the fuel inspection earlier to avoid duplicate work and conducting pre-inspections to identify issues ahead of time. "As any aircraft continues to age, you're going to see more and more issues that need to be repaired on a PDM line," said Col. Francis Marino, the B-2 system program manager within the Bombers Directorate, in a statement. He said that "the pre-inspection is great because it reduces the number of surprises at PDM." Maintaining the B-2's equipment and repair line is also critical. In May 2024, Northrop Grumman was awarded a substantial $7 billion contract for sustainment and support work, as well as planned upgrades. Better stealth and communications In order to keep the bombers hidden from potential countermeasures and threats, the Air Force has been at work on several important upgrades to its stealth, as well as its comms. Allen said that as part of a new program, the service is providing the B-2 with upgraded beyond-line-of-sight satellite communications capability, which "significantly improves the transfer time for real time mission planning data" and "will allow the operator to simultaneously receive and transmit voice communications and data which is an upgrade from what the aircraft currently has." The B-2's stealth capabilities, including its low-observable, radar-absorbent materials, are also being enhanced, which is set to further reduce its radar cross section, which refers to how the bomber appears to radar operators. The B-2 features a unique flying-wing airframe, edge alignment, and other technologies that dramatically reduce its signature across multiple frequency bands, making it difficult for enemy air-defense radars to detect, track, and target the aircraft. "Upgrading its avionics, sensors and communication systems are essential so that we stay ahead of emerging threats and enhance our payload and versatility," Lt. Col. Benjamin Elton, material leader, B-2 Integrated Capabilities Branch, said. Keeping B-2s in the fight B-2s will continue to be upgraded into the 2030s, when the Air Force plans to replace the aircraft with the new B-21 Raider, which is currently in initial production and testing after the plane took its first flight in late 2023. The B-21, also made by Northrop Grumman, will also replace the B-1 Lancer. Developments on the new bomber began in 2015. Many of the details on the B-21's abilities are classified, but it's expected that the aircraft will boast better stealth, payload capacity, communications, and sensors than its predecessor. That includes carrying weapons that haven't been invented yet. The costs and delivery dates of the B-21 program have shifted over the years, but it's expected to enter service this decade, and the aim is to produce at least 100 of them.
